Heron Therapeutics (HRTX) Short-term Investments (2015 - 2026)

Heron Therapeutics (HRTX) has 12 years of Short-term Investments data on file, last reported at $18.7 million in Q1 2026.

• Quarterly Short-term Investments fell 40.57% year-over-year to $18.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.7 million (down 40.57% YoY) and the FY2025 annual result came in at $18.0 million, down 46.29% from the prior year.
• Short-term Investments grew to $18.7 million in Q1 2026, from $18.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $71.3 million in Q3 2022 to a low of $12.4 million in Q3 2025.
• A 5-year average of $38.9 million and a median of $34.9 million in 2022 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2024 — Short-term Investments surged 147.5% — and 2025, when it plunged 72.49%.
• Tracing HRTX's Short-term Investments over 5 years: stood at $69.5 million in 2022, then decreased by 25.55% to $51.7 million in 2023, then plunged by 35.28% to $33.5 million in 2024, then sank by 46.29% to $18.0 million in 2025, then climbed by 3.8% to $18.7 million in 2026.
• The last three Short-term Investments figures came in at $18.7 million (Q1 2026), $18.0 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.